For the first time, scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified small molecules that allow for complete control over a genetic defect responsible for the most common adult onset form of muscular dystrophy. [ + ]

The Australian Government has released 15 Strategic Research Priorities as part of a process to establish a long-term vision for Australian research. [ + ]

Chemists have discovered that an ‘impossible’ reaction at cold temperatures actually occurs with vigour, which could change our understanding of how alcohols are formed and destroyed in space. [ + ]

REVA Medical (ASX:RVA) has commenced recruitment for the Australia/New Zealand arm of its CE Mark trial for ReZolve 2, a bioresorbable cardiac scaffold. [ + ]

AmpliPhi, the US bacteriophage company which merged with Australia’s Special Phage Services last year, has raised $7m in a private placement. [ + ]

Genetic differences between people who develop allergies and those who don’t have been identified. [ + ]

The report ‘Inspiring industry to inspire Australia’ has been released, highlighting 15 industry initiatives that are fostering an appreciation of science in schools, communities and the workforce, and its potential to improve our world. [ + ]

A Bill was yesterday introduced into parliament to jointly legislate for quarterly credits for companies entitled to the refundable 45% R&D Tax Incentive and to enact the $20 billion turnover cap for companies to be eligible for the 40% non-refundable R&D tax offset, as announced as part of the government’s A Plan for Australian Jobs in February. [ + ]

A PhD scholarship for Aboriginal and Torres Strait Islander students has been created by Andrology Australia. [ + ]

Mesoblast (ASX:MSB) has been granted ethics approval for a phase II trial of its mesenchymal precursor cells in patients with diabetic nephropathy. [ + ]

In a whole-of-government approach to investing in research, the Australian Government announced 15 Strategic Research Priorities (SRPs) this week. [ + ]

LBT Innovations (ASX:LBT) will enter a 50/50 JV with Switzerland’s Hettich to oversee final development and distribution of lab screening platform APAS. [ + ]

Genetic Technologies (ASX:GTG) says an Australian academic study supports the effectiveness of including genotypes used in its BREVAGen test to improve breast cancer risk assessment. [ + ]

New insights into how bacteria colonise surfaces may help deal with biofilms that develop on implanted medical devices. [ + ]

With early-bird registrations about to close (28 June), preparations have kicked into top gear at AusBiotech as the team prepares to return the industry event of the year to Brisbane, Queensland, from 30 October-1 November 2013. [ + ]